SNCA and LRRK2

SNCA and LRRK2 are two genes central to the modern understanding of Parkinson's disease (PD) pathology. Although most cases of PD are considered sporadic, with no known cause, a significant minority are linked to genetic factors, and mutations in these two genes are the most prominent. The SNCA gene provides the instructions for making alpha-synuclein, a protein abundant in the brain. While its exact function is not fully understood, it is believed to play a role in regulating the release of neurotransmitters. Certain mutations in SNCA, including point mutations and duplications or triplications of the gene, lead to the overproduction or misfolding of the alpha-synuclein protein. This misfolded protein is the primary component of Lewy bodies, the toxic protein clumps that are the pathological hallmark of Parkinson's disease and are thought to cause the death of dopamine-producing neurons.

The LRRK2 gene codes for an enzyme called Leucine-rich repeat kinase 2, also known as dardarin. This enzyme is involved in various cellular processes, including waste disposal (autophagy) and vesicle trafficking. Mutations in LRRK2, particularly the G2019S mutation, cause the kinase to become hyperactive. This overactivity is believed to disrupt normal cellular function, leading to neuronal stress and eventual cell death. Unlike many other genetic forms of PD, the clinical presentation of LRRK2-associated Parkinson's is often indistinguishable from the sporadic form of the disease.

The discovery of SNCA in 1997 and LRRK2 in 2004 revolutionized the field of Parkinson's research, confirming that the disease could have a clear genetic origin. These genes are inherited in an autosomal dominant pattern, meaning only one copy of the mutated gene is needed to significantly increase the risk of developing PD. This contrasts with other PD-related genes, such as PRKN (Parkin) and PINK1, which are typically inherited in an autosomal recessive pattern and are associated with early-onset forms of the disease. While mutations in SNCA and LRRK2 are causative in some families, they are more broadly considered major risk factors. The presence of a LRRK2 mutation, for example, does not guarantee that an individual will develop PD, highlighting the complex interplay between genetic predisposition and environmental or other biological factors.

Understanding the roles of SNCA and LRRK2 has profound significance for both patients and researchers. For patients, genetic testing can provide a definitive diagnosis, inform family members of their potential risk, and allow for participation in gene-specific clinical trials. For science, these genes provide a crucial window into the molecular mechanisms that drive neurodegeneration in all forms of Parkinson's disease, not just the genetic ones. The pathways involving alpha-synuclein aggregation and LRRK2 kinase activity are now considered central to PD pathology. Consequently, they have become the most promising targets for the development of disease-modifying therapies. Drugs aimed at reducing alpha-synuclein levels or inhibiting the LRRK2 kinase are currently in advanced stages of clinical development, offering the first real hope for treatments that could slow or halt the progression of Parkinson's disease.